Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus’ vice president, finance and chief financial officer, is scheduled to present a corporate update at the Stephens 2016 Fall Investment Conference at 9:00am ET on Tuesday, November 8, 2016.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus CorporationStacey Leanos, 925-288-6137Associate Director, Investor & Public Relationsir@cerus.com

Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Cerus Charts.
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Cerus Charts.